+

WO2006017171A3 - Methodes de diagnostic et de traitement de l'obesite, du diabete et de l'insulinoresistance - Google Patents

Methodes de diagnostic et de traitement de l'obesite, du diabete et de l'insulinoresistance Download PDF

Info

Publication number
WO2006017171A3
WO2006017171A3 PCT/US2005/024256 US2005024256W WO2006017171A3 WO 2006017171 A3 WO2006017171 A3 WO 2006017171A3 US 2005024256 W US2005024256 W US 2005024256W WO 2006017171 A3 WO2006017171 A3 WO 2006017171A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
methods
diagnosing
insulin resistance
treating obesity
Prior art date
Application number
PCT/US2005/024256
Other languages
English (en)
Other versions
WO2006017171A2 (fr
Inventor
Shonna A Moodie
Fang Zhang
Paul G Rack
Jin Shang
Daniel M Joo
Chi-Wai Wong
Francine Gregoire
Original Assignee
Metabolex Inc
Shonna A Moodie
Fang Zhang
Paul G Rack
Jin Shang
Daniel M Joo
Chi-Wai Wong
Francine Gregoire
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolex Inc, Shonna A Moodie, Fang Zhang, Paul G Rack, Jin Shang, Daniel M Joo, Chi-Wai Wong, Francine Gregoire filed Critical Metabolex Inc
Priority to JP2007521515A priority Critical patent/JP2008506949A/ja
Publication of WO2006017171A2 publication Critical patent/WO2006017171A2/fr
Publication of WO2006017171A3 publication Critical patent/WO2006017171A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des compositions et des méthodes destinées au diagnostic et au traitement de l'obésité, du diabète et de l'insulinorésistance. L'invention concerne plus particulièrement des méthodes destinées à l'identification de modulateurs des polynucléotides ou polypeptides de l'invention et à l'utilisation de ces modulateurs pour le traitement de l'obésité et/ou du diabète, ainsi que des méthodes de diagnostic de l'obésité et/ou du diabète, consistant à mesurer les niveaux de polynucléotides ou de polypeptides de l'invention chez un patient.
PCT/US2005/024256 2004-07-13 2005-07-07 Methodes de diagnostic et de traitement de l'obesite, du diabete et de l'insulinoresistance WO2006017171A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007521515A JP2008506949A (ja) 2004-07-13 2005-07-07 肥満、糖尿病およびインスリン抵抗性の診断および治療の方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58778004P 2004-07-13 2004-07-13
US60/587,780 2004-07-13

Publications (2)

Publication Number Publication Date
WO2006017171A2 WO2006017171A2 (fr) 2006-02-16
WO2006017171A3 true WO2006017171A3 (fr) 2009-06-11

Family

ID=35839747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/024256 WO2006017171A2 (fr) 2004-07-13 2005-07-07 Methodes de diagnostic et de traitement de l'obesite, du diabete et de l'insulinoresistance

Country Status (2)

Country Link
JP (1) JP2008506949A (fr)
WO (1) WO2006017171A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008502307A (ja) * 2003-10-28 2008-01-31 プロテミックス ディスカバリー リミティド 抗肥満活性及び他の関連用途を有するペプチド
US20080200568A1 (en) * 2005-08-30 2008-08-21 Stephanie Chissoe Genes Associated With Type ll Diabetes Mellitus
WO2007106488A2 (fr) * 2006-03-13 2007-09-20 Wyeth Modulateurs de la gluconeogenese
WO2008061902A2 (fr) * 2006-11-24 2008-05-29 Vrije Universiteit Brussel Ciblage de l-3-hydroxyacyl-coenzyme a déshydrogénase, à chaîne courte (hadhsc) dans les troubles de l'homéostasie glucosique
US8569232B2 (en) 2007-10-31 2013-10-29 Kobe University Therapeutic agent for diabetes
WO2012051567A2 (fr) * 2010-10-15 2012-04-19 The Trustees Of Columbia University In The City Of New York Gènes de l'obésité, leurs protéines et leurs utilisations
EP2524927A1 (fr) * 2011-05-20 2012-11-21 Covagen AG Nouveaux composés de liaison de chymase et utilisations médicales associées
US11154591B2 (en) 2016-10-14 2021-10-26 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
JP2018068235A (ja) * 2016-10-31 2018-05-10 国立大学法人神戸大学 抗インスリン抵抗性物質スクリーニング方法
KR20210006916A (ko) 2018-05-07 2021-01-19 젠와인 바이오테크놀로지 게엠바하 미생물 발효에 의해 수득된 탄수화물로부터 락토-Ｎ-네오테트라오스 (LNnT)를 정제하기 위한 간단한 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028479A2 (fr) * 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003082335A1 (ja) * 2002-04-03 2005-07-28 住友製薬株式会社 新規血糖調節薬及びそのスクリーニング方法
US6854933B2 (en) * 2002-08-07 2005-02-15 Deepwater Technologies, Inc. Vertically restrained centerwell SPAR
WO2004053124A1 (fr) * 2002-12-06 2004-06-24 Shionogi & Co., Ltd. Procede de criblage d'un remede ou d'un agent preventif contre le diabete

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028479A2 (fr) * 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis

Also Published As

Publication number Publication date
WO2006017171A2 (fr) 2006-02-16
JP2008506949A (ja) 2008-03-06

Similar Documents

Publication Publication Date Title
WO2008030273A3 (fr) Compositions et procédés pour le diagnostic et le traitement du diabète de type 2
WO2006040129A3 (fr) Conjugues de proteine utilisables en therapie, pour le diagnostic et en chromatographie
TW200608961A (en) Methods and reagents for the treatment of metabolic disorders
WO2007079171A3 (fr) Traitement du lymphome de hodgkin
IL198922A0 (en) Chemical compounds and uses
WO2008055491A3 (fr) Diagnostic et stratification des risques de diabète sucré par mr-proadm
WO2004110375A3 (fr) Polytherapie permettant de traiter le diabete
WO2008036341A3 (fr) Compositions et procédés concernant des anticorps de récepteur du glucagon
WO2008065372A3 (fr) Polypeptides d'érythropoïétine modifiés et utilisation de ceux-ci dans des traitements
WO2007111864A3 (fr) Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation
WO2007092640A3 (fr) Anticorps qui se lient à par-2
WO2006053043A3 (fr) Methodes de traitement du diabete sucre
WO2009023048A3 (fr) Marqueurs du syndrome métabolique
WO2011002834A3 (fr) Compositions et procédés de diagnostic et de traitement du diabète de type i
WO2006017171A3 (fr) Methodes de diagnostic et de traitement de l'obesite, du diabete et de l'insulinoresistance
WO2003101284A3 (fr) Procedes de diagnostic et de traitement de diabetes et de l'insulinoresistance
WO2007079312A3 (fr) Compositions et procédés de traitement d’affections pathologiques médiées par l'actine
WO2008065682A3 (fr) Variantes génétiques de susceptibilité au diabète mellitus de type 2
WO2005034737A3 (fr) Diagnostic et traitement de troubles du reticulum endoplasmique
DE602005027400D1 (de) Il-22 zur behandlung von fettleibigkeit, diabetes, hyperlipidämie, hyperglykämie und insulinresistenz
WO2003103597A3 (fr) Diagnostic et traitement du diabete et de la resistance insulinique
WO2003102161A3 (fr) Methodes de diagnostic et de traitement du diabete et de l'insulinoresistance
WO2003103601A3 (fr) Methodes de diagnostic et de traitement du diabete et de la resistance a l'insuline
WO2008059041A3 (fr) Complémentation d'un déficit de facteur xi par mutants de facteur v
WO2006010051A3 (fr) Methodes de diagnostic et de traitement de diabetes et de resistance a l'insuline

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007521515

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载